相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better?
John H. Strickler et al.
CLINICAL CANCER RESEARCH (2021)
A Gene Mutation Signature Predicting Immunotherapy Benefits in Patients With NSCLC
Dong Pan et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Plasma Tumor Mutation Burden and Response to Pembrolizumab-Letter
Zhiqiang Xue et al.
CLINICAL CANCER RESEARCH (2021)
Identification of Deleterious NOTCH Mutation as Novel Predictor to Efficacious Immunotherapy in NSCLC
Kai Zhang et al.
CLINICAL CANCER RESEARCH (2020)
Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient
Giovanni Rossi et al.
CANCERS (2020)
Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort study
Xue Bai et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden
D. Marinelli et al.
ANNALS OF ONCOLOGY (2020)
The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee
Lynette Sholl et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
Aurelien Marabelle et al.
LANCET ONCOLOGY (2020)
EPHA mutation as a predictor of immunotherapeutic efficacy in lung adenocarcinoma
Hua Bai et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Tony S. K. Mok et al.
LANCET (2019)
Stereotactic Radiofrequency Ablation of Liver Tumors in Octogenarians
Peter Schullian et al.
FRONTIERS IN ONCOLOGY (2019)
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Robert M. Samstein et al.
NATURE GENETICS (2019)
Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy
Ferdinandos Skoulidis et al.
NATURE REVIEWS CANCER (2019)
PD-L1 Testing in Non-small Cell Lung Cancer: Past, Present, and Future
Hyojin Kim et al.
JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE (2019)
Interferon Gamma Messenger RNA Signature in Tumor Biopsies Predicts Outcomes in Patients with Non-Small Cell Lung Carcinoma or Urothelial Cancer Treated with Durvalumab
Brandon W. Higgs et al.
CLINICAL CANCER RESEARCH (2018)
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Comutations in DNA Damage Response Pathways Serve as Potential Biomarkers for Immune Checkpoint Blockade
Zhijie Wang et al.
CANCER RESEARCH (2018)
Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors
Diana Miao et al.
NATURE GENETICS (2018)
Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy
Jean-David Fumet et al.
BRITISH JOURNAL OF CANCER (2018)
Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
Zhong-Yi Dong et al.
CLINICAL CANCER RESEARCH (2017)
IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade
Mark Ayers et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
High performance of targeted next generation sequencing on variance detection in clinical tumor specimens in comparison with current conventional methods
Dan Su et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2017)
Tumour-associated macrophages as treatment targets in oncology
Alberto Mantovani et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer
D. P. Carbone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia
Klaus H. Metzeler et al.
BLOOD (2016)
FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)
Masaru Katoh
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Regulation of Tumor Metastasis by Myeloid-Derived Suppressor Cells
Thomas Condamine et al.
ANNUAL REVIEW OF MEDICINE, VOL 66 (2015)
Targeting FGFR Signaling in Cancer
Mehdi Touat et al.
CLINICAL CANCER RESEARCH (2015)
Fibroblast growth factor receptor (FGFR) gene amplifications are rare events in bladder cancer
Anna Fischbach et al.
HISTOPATHOLOGY (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Clonal status of actionable driver events and the timing of mutational processes in cancer evolution
Nicholas McGranahan et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
FGFR4 Gly388Arg polymorphism contributes to prostate cancer development and progression: A meta-analysis of 2618 cases and 2305 controls
Bin Xu et al.
BMC CANCER (2011)
FGF19 Regulates Cell Proliferation, Glucose and Bile Acid Metabolism via FGFR4-Dependent and Independent Pathways
Ai-Luen Wu et al.
PLOS ONE (2011)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
分享论文
